Viking Therapeutics (VKTX) Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of VK2735
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
| ING Van Kampen Equity Growth Fund S 2 Class (NASDAQ: VKTX) | Delayed: 26.86 +1.50 (5.91%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $25.36 | 52 Week High | $5.17 | |||
| Open | $24.38 | 52 Week Low | $0.94 | |||
| Day High | $27.76 | P/E | N/A | |||
| Day Low | $24.38 | EPS | $0.00 | |||
| Volume | 6,753,413 | |||||
